Nils Lycke

Overview

Best Publications

• Recent progress in mucosal vaccine development: potential and limitations

  Nils Lycke

  849
  Citations

• Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens

  N Lycke;J Holmgren

  524
  Citations

• Cholera toxin and cholera B subunit as oral—mucosal adjuvant and antigen vector systems

  Jan Holmgren;Nils Lycke;Cecil Czerkinsky

  435
  Citations

• Murine CD4 T-cell response to Helicobacter infection: TH1 cells enhance gastritis and TH2 cells reduce bacterial load.

  Marjan Mohammadi;John Nedrud;Ray Redline;Nils Lycke

  375
  Citations

• The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity.

  Nils Lycke;Takao Tsuji;Jan Holmgren

  344
  Citations

• Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues.

  C Czerkinsky;M W Russell;N Lycke;M Lindblad

  323
  Citations

• Isolation of mouse small intestinal intraepithelial lymphocytes, Peyer's patch, and lamina propria cells.

  Leo Lefrançois;Nils Lycke

  283
  Citations

• Mucosal Immunity: Implications for Vaccine Development

  Jan Holmgren;Cecil Czerkinsky;Nils Lycke;Ann-Mari Svennerholm

  275
  Citations

• Impaired mucosal immune responses in interleukin 4-targeted mice.

  M Vajdy;M H Kosco-Vilbois;M Kopf;G Köhler

  273
  Citations

• Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells.

  Ali A. Akhiani;Jacques Pappo;Zita Kabok;Karin Schön

  270
  Citations

• Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response.

  M Johansson;K Schön;M Ward;N Lycke

  258
  Citations

• Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro.

  Annakari Bromander;Jan Holmgren;Nils Lycke

  238
  Citations

• Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.

  L C Agren;L Ekman;B Löwenadler;N Y Lycke

  229
  Citations

• Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

  Marina De Filette;Walter Fiers;Wouter Martens;Ashley Birkett

  197
  Citations

• The regulation of gut mucosal IgA B-cell responses: recent developments

  N Y Lycke;M Bemark

  196
  Citations

• Gut IgA class switch recombination in the absence of CD40 does not occur in the lamina propria and is independent of germinal centers.

  Peter Bergqvist;Eva Gärdby;Anneli Stensson;Mats Bemark

  196
  Citations

• The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.

  Marina De Filette;Anna Ramne;Ashley Birkett;Nils Lycke

  182
  Citations

• CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.

  Dubravka Grdic Eliasson;Karim El Bakkouri;Karin Schön;Anna Ramne

  175
  Citations

• The Cholera Toxin-Derived CTA1-DD Vaccine Adjuvant Administered Intranasally Does Not Cause Inflammation or Accumulate in the Nervous Tissues

  Anna M. Eriksson;Karin M. Schön;Nils Y. Lycke

  169
  Citations

• Lack of J Chain Inhibits the Transport of Gut IgA and Abrogates the Development of Intestinal Antitoxic Protection

  Nils Lycke;Lena Erlandsson;Lena Ekman;Karin Schön

  161
  Citations